Zealand Pharma — September 2024
-
Diabetes præparater: Interessant sydkoreansk demens studie https://proinvestor.com/boards/122128
-
OVERBLIK: Disse selskaber er shortet på det danske aktiemarked https://proinvestor.com/investornyt/1211016/overblik-disse-selskaber-er-shortet-pa-det-danske-aktiemarked
-
Roche er i modvind på fedmekandidat https://proinvestor.com/investornyt/1211195/roche-er-i-modvind-pa-fedmekandidat
-
Zealand Pharma announces positive topline results from 13-week Phase 1b multiple ascending dose clinical trial with GLP-1/GLP-2 receptor dual agonist dapiglutide
Placebo-adjusted reductions in body weight of up to a mean of 8.3% with dapiglutide after 13 weekly doses
Dapiglutide treatment with doses up to 13 mg was assessed to be safe and well-tolerated with gastrointestinal adverse events consistent with the profile reported with other incretin-based therapies -
Læs hele meddelelsen: https://proinvestor.com/boards/122170
-
Mandagens aktier: Zealand i slutspurt i generelt positivt marked https://proinvestor.com/investornyt/1211235/mandagens-aktier-zealand-i-slutspurt-i-generelt-positivt-marked
-
Zealand Pharmas fedmemiddel viser gode takter i fase 1b-forsøg med højere doser https://proinvestor.com/investornyt/1211241/zealand-pharmas-fedmemiddel-viser-gode-takter-i-fase-1b-forsog-med-hojere-doser
-
Dapiglutide er en GLP-1/GLP-2 receptor dobbeltagonist, som udvikles til behandling af fedme og til at adressere low-grade
inflammation, som er en tilstand hos mange personer med overvægt og fedme, hvor fedtvævet er med til at skabe en kronisk
betændelsestilstand i kroppen -
Godmorgen
-
Zealands kursmål løftet 5 pct. af BTGI https://proinvestor.com/investornyt/1211523/zealands-kursmal-loftet-5-pct-af-btgi
-
OVERBLIK: Disse selskaber er shortet på det danske aktiemarked https://proinvestor.com/investornyt/1211530/overblik-disse-selskaber-er-shortet-pa-det-danske-aktiemarked
-
Aktier/tendens: Zealand kan løbe med opmærksomheden efter nyt fedmestudie https://proinvestor.com/investornyt/1211536/aktier-tendens-zealand-kan-lobe-med-opmaerksomheden-efter-nyt-fedmestudie
-
Hmm ES, Gubra har vist haft et middel kaldet GUB09-123 i pipeline https://www.infona.pl/resource/bwmeta1.element.elsevier-7f27808c-1487-345c-8584-7664c5a777ec/tab/summary
-
Aktier/åbning: Zealand dratter efter studietal og får følge af GN og Demant https://proinvestor.com/investornyt/1211549/aktier-abning-zealand-dratter-efter-studietal-og-far-folge-af-gn-og-demant
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind